Gene therapy for osteoarthritis

Steven C. Ghivizzani, Christopher H Evans

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Osteoarthritis (OA) is an incurable, chronic, painful, debilitating joint disease characterized primarily by the gradual erosion of protective articular cartilage. Although joint damage contributes to the onset of OA, the continued synthesis of inflammatory cytokines, such as interleukin-1, by synovial cells and chondrocytes is thought to drive the progression of disease. Numerous naturally occurring proteins have been identified with the potential to block inflammatory processes, or alternatively, stimulate the repair of damaged cartilage. Problems lie in the lack of effective methods of delivery, as most proteins have limited half-lives in vivo. Through the use of gene therapy applications, exogenous transgenes can be delivered to cells and tissues of arthritic joints, thereby redirecting their biology for sustained, local synthesis of therapeutic transgene products. A wide variety of transgenes and methods of delivery are currently under investigation for their capacity to block ongoing inflammation or stimulate repair and regeneration of cartilage tissues in OA.

Original languageEnglish (US)
Title of host publicationMilestones in Drug Therapy
Pages91-112
Number of pages22
StatePublished - 2010
Externally publishedYes

Publication series

NameMilestones in Drug Therapy

Fingerprint

Transgenes
Osteoarthritis
Genetic Therapy
Cartilage
Joints
Joint Diseases
Articular Cartilage
Chondrocytes
Interleukin-1
Arthritis
Disease Progression
Regeneration
Proteins
Cytokines
Inflammation
Therapeutics

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Drug Discovery

Cite this

Ghivizzani, S. C., & Evans, C. H. (2010). Gene therapy for osteoarthritis. In Milestones in Drug Therapy (pp. 91-112). (Milestones in Drug Therapy).

Gene therapy for osteoarthritis. / Ghivizzani, Steven C.; Evans, Christopher H.

Milestones in Drug Therapy. 2010. p. 91-112 (Milestones in Drug Therapy).

Research output: Chapter in Book/Report/Conference proceedingChapter

Ghivizzani, SC & Evans, CH 2010, Gene therapy for osteoarthritis. in Milestones in Drug Therapy. Milestones in Drug Therapy, pp. 91-112.
Ghivizzani SC, Evans CH. Gene therapy for osteoarthritis. In Milestones in Drug Therapy. 2010. p. 91-112. (Milestones in Drug Therapy).
Ghivizzani, Steven C. ; Evans, Christopher H. / Gene therapy for osteoarthritis. Milestones in Drug Therapy. 2010. pp. 91-112 (Milestones in Drug Therapy).
@inbook{20dfc63c194b48388a0a26bb5d09bb47,
title = "Gene therapy for osteoarthritis",
abstract = "Osteoarthritis (OA) is an incurable, chronic, painful, debilitating joint disease characterized primarily by the gradual erosion of protective articular cartilage. Although joint damage contributes to the onset of OA, the continued synthesis of inflammatory cytokines, such as interleukin-1, by synovial cells and chondrocytes is thought to drive the progression of disease. Numerous naturally occurring proteins have been identified with the potential to block inflammatory processes, or alternatively, stimulate the repair of damaged cartilage. Problems lie in the lack of effective methods of delivery, as most proteins have limited half-lives in vivo. Through the use of gene therapy applications, exogenous transgenes can be delivered to cells and tissues of arthritic joints, thereby redirecting their biology for sustained, local synthesis of therapeutic transgene products. A wide variety of transgenes and methods of delivery are currently under investigation for their capacity to block ongoing inflammation or stimulate repair and regeneration of cartilage tissues in OA.",
author = "Ghivizzani, {Steven C.} and Evans, {Christopher H}",
year = "2010",
language = "English (US)",
isbn = "9783034602402",
series = "Milestones in Drug Therapy",
pages = "91--112",
booktitle = "Milestones in Drug Therapy",

}

TY - CHAP

T1 - Gene therapy for osteoarthritis

AU - Ghivizzani, Steven C.

AU - Evans, Christopher H

PY - 2010

Y1 - 2010

N2 - Osteoarthritis (OA) is an incurable, chronic, painful, debilitating joint disease characterized primarily by the gradual erosion of protective articular cartilage. Although joint damage contributes to the onset of OA, the continued synthesis of inflammatory cytokines, such as interleukin-1, by synovial cells and chondrocytes is thought to drive the progression of disease. Numerous naturally occurring proteins have been identified with the potential to block inflammatory processes, or alternatively, stimulate the repair of damaged cartilage. Problems lie in the lack of effective methods of delivery, as most proteins have limited half-lives in vivo. Through the use of gene therapy applications, exogenous transgenes can be delivered to cells and tissues of arthritic joints, thereby redirecting their biology for sustained, local synthesis of therapeutic transgene products. A wide variety of transgenes and methods of delivery are currently under investigation for their capacity to block ongoing inflammation or stimulate repair and regeneration of cartilage tissues in OA.

AB - Osteoarthritis (OA) is an incurable, chronic, painful, debilitating joint disease characterized primarily by the gradual erosion of protective articular cartilage. Although joint damage contributes to the onset of OA, the continued synthesis of inflammatory cytokines, such as interleukin-1, by synovial cells and chondrocytes is thought to drive the progression of disease. Numerous naturally occurring proteins have been identified with the potential to block inflammatory processes, or alternatively, stimulate the repair of damaged cartilage. Problems lie in the lack of effective methods of delivery, as most proteins have limited half-lives in vivo. Through the use of gene therapy applications, exogenous transgenes can be delivered to cells and tissues of arthritic joints, thereby redirecting their biology for sustained, local synthesis of therapeutic transgene products. A wide variety of transgenes and methods of delivery are currently under investigation for their capacity to block ongoing inflammation or stimulate repair and regeneration of cartilage tissues in OA.

UR - http://www.scopus.com/inward/record.url?scp=79953671803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953671803&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:79953671803

SN - 9783034602402

T3 - Milestones in Drug Therapy

SP - 91

EP - 112

BT - Milestones in Drug Therapy

ER -